Why did Indegene (INDGN) stock move recently?

On 7/27/2026, Indegene moved +3.1% — No specific catalyst identified in today's coverage; the stock rose amid interest in its upcoming dividend (record date July 31) as noted in analysis pieces, but moved broadly in line with the market. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Indegene (INDGN) overvalued or fairly valued?

MarketChacha shows Indegene's valuation in context — a forward P/E of about 21.7, a price-to-book of about 4.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Indegene's revenue?

Indegene reported revenue of ₹1,221 Cr for FY2026, with net profit of ₹212 Cr, per official filings.

What is the share price of Indegene (INDGN)?

Indegene last traded at ₹588.30 (-1.7% on the day), as of 10/19/2026 — a delayed quote shown for education, not investment advice.

Indegene

INDGN · NSE · Healthcare/Tech · India

Snapshot

TickerINDGN

ExchangeNSE

SectorHealthcare/Tech

IndustryHealth Information Services

CountryIndia

Employees4,687

HeadquartersBengaluru, India

Websitewww.indegene.com

Filings tracked11

About Indegene

Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, North America, and internationally. It operates through Enterprise Medical Solutions, Enterprise Commercial Solutions, and Other segments. The company provides AI-embedded commercialization services for biopharmaceutical, emerging biotech, and medical devices companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms, as well as provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Further, it engages in the professional, and scientific and technical activities. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.

Who owns it

Promoters55.5%
Institutions27.8%
Public & other16.8%

42 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 2.9 points over the period — profitability is trending down.

Net margin trend14.3% → 11.4%

Margin has compressed by about 2.9 points over the period — profitability is trending down.

Growth qualityrev 11% · PAT 6%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹1,128 Cr · EPS 6.10

Est. earnings growth +43.2%

Next fiscal year

Rev ₹5,046 Cr · EPS 27.17

Est. earnings growth +23.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹3,511 Cr

Net margin

11.4%

Profit CAGR (2y)

+9.1%

Net profit (FY2026)

₹401 Cr

Ask MarketChacha about INDGN

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 27, 2026
No specific catalyst identified in today's coverage; the stock rose amid interest in its upcoming dividend (record date July 31) as noted in analysis pieces, but moved broadly in line with the market.
source 1 ↗· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹3,511 Cr	₹401 Cr	11.4%
FY2025	₹2,839 Cr	₹407 Cr	14.3%
FY2024	—	₹337 Cr	—

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹1,063 Cr	₹116 Cr	10.9%
Q4 FY26	₹1,003 Cr	₹80 Cr	7.9%
Q3 FY26	₹942 Cr	₹103 Cr	10.9%
Q2 FY26	₹804 Cr	₹102 Cr	12.7%
Q1 FY26	₹761 Cr	₹116 Cr	15.3%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Press Release / Media Release
Press Release
BSE9/23/2026
Restructuring
Disclosure under Regulation 30 of SEBI (LODR) Regulation, 2015 - Merger of Indirect Wholly owned subsidiaries of the Company in Germany
BSE9/10/2026
Update On Material Litigation
Update on Material Litigation under the Telephone Consumer Protection Act, 1991 involving Wholly-Owned Subsidiary, Indegene, Inc.
BSE8/19/2026
Transcript Of The 28Th Annual General Meeting Held On August 13, 2026
Transcript of the 28th Annual General Meeting held on August 13, 2026
BSE8/17/2026material
Change in Directorate
Appointment of Ms. Jill Mary De Simone (DIN: 11483134) as an independent Director of the Company
BSE8/17/2026
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Scrutinizer''s Report - 28th Annual General Meeting
BSE8/17/2026material
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for BPC Genesis Fund I- A SPV Ltd
BSE8/10/2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for BPC Genesis Fund I SPV Ltd
BSE8/10/2026
Investor Presentation
Analyst Presentation and fact sheet - financial results for the quarter ended June 30, 2026
BSE7/30/2026
Press Release / Media Release
Press Release
BSE7/30/2026
Monitoring Agency Report
Monitoring Agency Report
BSE7/30/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.